研究目的
Investigating the feasibility and efficacy of PDT for peripheral-type lung cancers using a new laser probe, the composite-type optical fiberscope (COF).
研究成果
PDT using the new laser probe, COF, was found to be a feasible and non-invasive treatment modality for early peripheral-type lung cancer, with potential to become a standard treatment option in the future.
研究不足
The study was a phase-I trial with a small sample size (7 patients), which may limit the generalizability of the findings. The long-term efficacy and safety of PDT for peripheral-type lung cancers need further investigation.
1：Experimental Design and Method Selection:
A phase-I, single-arm clinical trial was conducted to evaluate the feasibility and antitumor effect of PDT using talaporfin sodium and the new laser probe for peripheral-type lung cancers.
2：Sample Selection and Data Sources:
Patients with clinical stage IA peripheral lung cancers (primary tumor ≤20 mm in diameter) were included.
3：List of Experimental Equipment and Materials:
A diode laser emitting continuous-wave laser light at a wavelength of 664 nm and the composite-type optical fiberscope (COF) were used.
4：Experimental Procedures and Operational Workflow:
The photosensitizer, talaporfin sodium, was administered 4 to 6 hours prior to laser irradiation. The COF was introduced into the cancer lesion for laser irradiation.
5：Data Analysis Methods:
Evaluation was based on chest CT and transbronchial lung biopsy (TBLB) at 3, 6, 9, and 12 months after PDT.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
